摘要
目的探究益髓升血丸联合重组人红细胞生成素治疗化疗相关性贫血患者的疗效及对免疫功能的影响。方法便利选取该院2019年3月—2020年12月收治的96例化疗相关性贫血患者为研究对象,按照随机数字表法分成两组,选用重组人红细胞生成素治疗的48例患者为对照组,选择益髓升血丸联合重组人红细胞生成素治疗的48例患者为研究组,比较两组临床疗效及不良反应发生情况及治疗前后红细胞压积(HCT)、血红蛋白(Hb)、血小板(PLT)、红细胞(RBC)、转铁蛋白(TRF)及前白蛋白(PA)、T淋巴细胞亚群水平及Karnofsky评分。结果与对照组的83.33%总有效率相比,研究组的95.83%更高,差异有统计学意义(χ^(2)=4.019,P<0.05)。治疗后两组HCT、Hb、PLT、RBC水平均较治疗前升高,差异有统计学意义(P<0.05),且研究组HCT、Hb、PLT、RBC水平高于对照组,差异有统计学意义(P<0.05)。治疗后两组TRF、PA水平及Karnofsky评分均较治疗前升高,差异有统计学意义(P<0.05),且研究组TRF、PA水平及Karnofsky评分高于对照组,差异有统计学意义(P<0.05)。与治疗前比较,治疗后两组的CD4^(+)、CD4^(+)/CD8^(+)显著升高,差异有统计学意义(P<0.05),CD8^(+)水平差异无统计学意义(P>0.05);治疗后研究组的CD4^(+)、CD4^(+)/CD8^(+)均高于对照组,差异有统计学意义(P<0.05),CD8^(+)水平比较,差异无统计学意义(P>0.05)。与对照组不良反应发生率10.42%相比,研究组12.50%稍高,但差异无统计学意义(P>0.05)。结论益髓升血丸联合重组人红细胞生成素治疗化疗相关性贫血的疗效显著,能改善患者营养状况,提升免疫功能,且治疗安全性较高。
Objective To explore the efficacy of Yisui Shengxue Pill combined with recombinant human erythropoietin in the treatment of patients with chemotherapy-related anemia and its effect on immune function.Methods 96 patients with chemotherapy-related anemia admitted to the hospital from March 2019 to December 2020 were conveniently selected as the research objects.They were divided into two groups according to the random number table method.48 patients treated with recombinant human erythropoietin were selected as the control group.Forty-eight patients treated with Yisui Shengxue Pills combined with recombinant human erythropoietin were selected as the study group.The clinical efficacy,adverse reactions,well as hematocrit(HCT),hemoglobin(Hb)and platelets(PLT),red blood cell(RBC),transferrin(TRF)and prealbumin(PA),T lymphocyte subgroup levels and Karnofsky score before and after treatment of the two groups were compared.Results Compared with the total effective rate of 83.33%in the control group,95.83%in the study group was higher,and the difference was statistically significant(χ^(2)=4.019,P<0.05).After treatment,the levels of HCT,Hb,PLT,and RBC in the two groups were higher than before treatment,the difference was statistically significant(P<0.05),and the levels of HCT,Hb,PLT,and RBC in the study group were higher than those in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of TRF,PA and Karnofsky score in the two groups were higher than before treatment,the difference was statistically significant(P<0.05),and the TRF,PA levels and Karnofsky score of the study group were higher than those of the control group,the difference was statistically significant(P<0.05).Compared with before treatment,CD4^(+),CD4^(+)/CD8^(+) in the two groups were significantly increased after treatment,the difference was statistically significant(P<0.05),and the difference in CD8^(+) levels was not statistically significant(P>0.05);CD4^(+)/CD8^(+) were higher than the control group,the d
作者
焦宁
俆雨
毛毛
许冬鑫
张登山
JIAO Ning;XU Yu;MAO Mao;XU Dongxin;ZHANG Dengshan(Department of Oncology,Zibo Hospital of Traditional Chinese Medicine,Zibo,Shandong Province,255300 China;Department of Gynecology,Zibo Hospital of Traditional Chinese Medicine,Zibo,Shandong Province,255300 China)
出处
《中外医疗》
2021年第32期26-30,共5页
China & Foreign Medical Treatment
基金
山东省中医药科技项目(2020M113)。
关键词
益髓升血丸
重组人红细胞生成素
化疗相关性贫血
免疫功能
Yisui Shengxue Pill
Recombinant human erythropoietin
Chemotherapy-related anemia
Immune function
